Diabetic Macular Edema Market
Diabetic Macular Edema Market By Drug, Form, Distribution Channel & Region | Forecast 2022 to 2032
Will Anti-VEGF Provide Better Outcomes in Diabetic Macular Edema Treatment? Discover Exclusive Insights in FMI's Report!
Diabetic Macular Edema Market Outlook (2022 to 2032)
[250 Pages Report] The global diabetic macular edema market size is expected to reach a valuation of US$ 3.7 Billion by the end of 2022, and further expand at a CAGR of 1.2% from 2022 to 2032. The market is projected to reach a valuation of ~US$ 4.2 Billion by the end of 2032. Anti-VEGF products are leading the market in terms of drugs and they held a share of about 95.5% in 2021 in the global market. Below-mentioned factors are expected to play a pivotal role in furthering market growth:
- Increase in the global epidemic of type II diabetes mellitus and subsequent onset of co-morbidities, including vision loss
- Manufacturers are emphasizing offering corticosteroid implants, eliminating the need for frequent intravitreal injections
- Discovery of innovative therapeutics, such as Iluvein, to act as a major growth catalyst
- Established market players are emphasizing on licensing and patenting of their products, giving them a competitive edge
|
Attributes |
Key Statistics |
|
Global Diabetic Macular Edema Market Estimated Size (2022E) |
US$ 3.7 Billion |
|
Projected Market Valuation (2032F) |
US$ 4.2 Billion |
|
Value-based CAGR (2022 to 2032) |
1.2% |
|
Collective Value Share: Top 5 Countries |
71.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising Global Burden of Type II Diabetes presenting Major Expansion Opportunities
The World Health Organization estimates that the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Between 2000 and 2019, there was a 3% increase in diabetes mortality rates by age. Type 2 diabetes results from the body’s ineffective use of insulin. More than 95% of people with diabetes have type 2 diabetes.
One of the major symptoms manifesting among diabetic patients is diabetic macular edema. Generally, the initial stages of diabetic macular edema exhibit no symptoms, which leads doctors to let it remain undiagnosed. As the edema spreads to encompass the central macula, however, patients generally experience progressive vision loss that occurs anywhere from weeks to months after the initial symptom. The global prevalence of DME among individuals with T1DM or T2DM varies by geographic region, with rates as low as 11.4% in European countries to as high as 45.3% in North American countries.
Considering these facts and figures, the global healthcare industry has been working unceasingly to develop therapeutic approaches to treat diabetic macular edema. In recent years, various advancements have translated into extensive clinical trials intended to develop treatment approaches, with largely positive outcomes. Intensive treatment has been consistently shown to substantially reduce the risk and progression of retinopathy and microvascular complications.
The USA to emerge as a highly Remunerative Market for Diabetic Macular Edema
Within North America, the USA is expected to generate significant growth prospects for the diabetic macular edema market. As per FMI, the country accounted for nearly 3/5th of total market revenue in 2021. Diabetes mellitus (DM) is a rapidly growing epidemic in the United States, and it is expected to affect 592 million individuals within the next 20 years. Diabetic retinopathy (DR) and diabetic macular edema (DME) are the 2 most common ophthalmic complications of DM.
DR is the leading cause of blindness among working-age adults around the world and the development of DR is tied to DM disease duration. With the only identifier of early markers of DR being a complete ophthalmic exam, early signs of the disease are asymptomatic.
Yearly, or at least every other year, ophthalmic exams are recommended for all patients with DM; but often, individuals with DM have not undergone screening exams and do not have regular eye exams until vision loss has occurred. With spending estimates of $490 million to treat the vision complications of DM, it is clear that DR and DME impose a substantial burden on patients, caregivers, and healthcare systems.
The most frequent reason for visual loss in diabetic patients is diabetic macular edema (DME). Currently, the first-line treatment for DME is vascular endothelial growth factor inhibitors (anti-VEGFs), while the second-line treatment is typically corticosteroid implants. By reducing the frequency of intravitreal injections, these implants are an efficient and safe therapeutic modality that can improve the quality of life for DME patients.
The most frequent cause of vision loss in people with diabetic retinopathy is diabetic macular edema (DME), whose incidence is rising due to the global epidemic of type II diabetes mellitus. Other biochemical processes involved in maintaining retinal vascular homeostasis are being investigated in pharmacologic research in the hopes of identifying novel therapeutic targets for conditions that are resistant to existing therapies.
Find your sweet spots for generating winning opportunities in this market.
2017 to 2021 Global Diabetic Macular Edema Demand Outlook Compared To 2022 to 2032 Forecast
The global diabetic macular edema market held approximately 77.0% of the overall global diabetes therapeutics market, which was worth ~US$ 4.2 Billion in 2021. Sales in the global diabetic macular edema market expanded at a CAGR of 18.1% from 2017 to 2021.
Diabetes mellitus (DM) is currently a serious health emergency. According to the World Health Organization (WHO), around 422 million people worldwide have diabetes as of 2022, and the condition is directly responsible for 1.5 million annual fatalities.
In Europe, 9.2% of adults have diabetes (61 million), 1 in 3 (33%) diabetic subjects remain undiagnosed, and 1 in 11 adults have the disease. These statistics come from the International Diabetes Federation (IDF) and are based on the data from 2021. By 2045, there will be a 13% rise in disease prevalence.
For many years, grid and focused laser photocoagulation was the gold standard of treatment for DME, which was the leading cause of moderate visual loss in diabetic subjects worldwide.
However, focal/grid laser therapy is now mostly used for DME that does not involve a center, according to the European Society of Retina Specialists (EURETINA) recommendations. The use of corticosteroid implants and anti-VEGFs in intravitreal therapy has transformed the medical treatment of DME in recent years.
With growing clinical studies presenting novel therapeutic modalities for the treatment of diabetic macular edema with high patient compliance and positive treatment outcomes, the market for diabetic macular edema is expected to witness growth at a CAGR of 1.2% during the forecast period from 2022 to 2032.
What Are The Key Trends Pushing Sales In Diabetic Macular Edema Market?
- Emergence of Innovative Therapeutics like Iluvien
Manufacturers operating in the diabetic macular edema market are presented with lucrative opportunities with the introduction of novel therapeutic modalities, which will aid in the suppression and management of macular edema.
Fluocinolone acetonide (FAc), a strong glucocorticoid receptor agonist, can be released continuously for up to 36 months using an intravitreal injectable non-biodegradable implant called Iluvien. Iluvien is typically used to treat DME in individuals who have previously taken a course of corticosteroids but did not see a significant rise in ocular pressure.
A phase 3 FAME clinical trial was used to assess Iluvien's clinical effectiveness, and numerous real-world reports have supported this finding. Notably, continuous dosing guarantees treatment even in cases where follow-up consultations are missed. This is a key benefit since a variety of variables can alter the strict dose regimen necessary for the best outcomes from anti-VEGF therapy.
The FDA has currently approved Iluvien for the treatment of DME. With the emergence of innovative therapeutics, the market for diabetic macular edema is set to propel at a profitable pace in terms of growth over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Which Factors Are Restraining The Demand In Diabetic Macular Edema Market?
Despite the clinical advantages of anti-VEGFs, these medications call for a number of intravitreal injections and follow-up appointments, which entails substantial direct expenditures for the healthcare system, as well as large indirect expenses for patients, their families, and society as a whole.
Additionally, due to the poor compliance of patients with these therapeutic regimens, the clinical effectiveness of these treatments after their discontinuation is low.
Furthermore, the global shortage of resources for diabetic eye care may not be entirely filled by reliance on eye care specialists and limited qualified personnel. These factors are set to cumulatively pose a restrictive impact on growth in the diabetic macular edema market over the forecast period.
Country-Wise Insights
What Makes the USA a Remunerative Diabetic Macular Edema Market?
“Rising Cases of Swelling in Retina due to Diabetes Will Propel Growth in the USA”
The USA held a total share of about 58.0% in 2021 in the diabetic macular edema market and is expected to continue to experience the same growth rate throughout the forecast period. The country is currently witnessing a high prevalence of diabetic macular edema and the market is expected to be propelled by the presence of renowned players.
The prevalence of diabetic macular edema in the USA was 3.8% or over 746,000 people belonging to the age group of 40 years and above, according to the American Journal of Managed Care (2018). The high prevalence is set to push growth in the USA
How will Sales in Germany's Diabetic Macular Edema Market Fare?
“Germany-based Pharmaceutical Companies to Invest in Macular Edema Vision Treatment”
Germany held a share of about 3.2% in the global diabetic macular edema market in 2021. To establish a strong position in the market for treating the growing number of eye diseases, pharmaceutical companies in the country are making huge investments in infrastructure, new technologies, and research & development activities. These factors are projected to drive the German market in the next decade.
Why is the Demand in Australia Diabetic Macular Edema Market Burgeoning?
“Australian Companies Are Distributing New Products for DME Eye Treatment”
Australia held approximately 3.0% of the share in the global market in 2021. Due to the growing need for innovative treatments for macular edema, major players are increasingly releasing their licensed products on the Australian market.
ILUVIEN (190 micrograms intravitreal implant in applicator) has been approved by the Australian Therapeutic Goods Administration (TGA), a division of the Australian Department of Health that regulates the availability of medical products, for the treatment of diabetic oedema (DME) in patients who have originally completed a course of corticosteroids, but did not have a clinically significant rise in intraocular pressure.
Alimera Sciences, Inc. made the announcement of its authorization in August 2019.
Category-Wise Insights
Which is the Highly Preferred Drug Used for Diabetic Macular Edema Treatment?
“Need for Anti-VEGF Drugs to Treat Diabetic Eye Disease Will Surge by 2032”
By drugs, the anti-VEGF segment held a share of around 95.5% in the global diabetic macular edema market in 2021. Extensive research activities by key companies and the introduction of advanced inhibitors to repress their causative effects, which may develop into a disease indication, are set to propel the segment in the evaluation period.
Which is the Most Common Form of Diabetic Macular Edema Treatment?
“Wet Macular Degeneration to Be Treated with Intravitreal Injections”
Intravitreal injections held the highest global market share of about 94.8% in 2021. Anti-VEGF therapies are commonly administered through intravitreal injections to slow down or reverse macular edema. With anti-VEGF therapies as a majorly adopted treatment modality, the intravitreal injections segment would gain traction in terms of adoption.
Which Distribution Channel Would Benefit the Diabetic Macular Edema Industry?
“Patients Suffering from Diabetic Edema to Visit Hospitals for Quality Care”
Hospitals held a revenue share of about 49.5% in 2021 in the global market. Hospitals would dominate in terms of product distribution in the global diabetic macular edema market owing to the easy availability of trained professionals, advanced treatment modalities, and reimbursement for procedures in hospital settings.
Competitive Landscape
Key players in the diabetic macular edema market are focusing on robust research and development activities. There is currently a large clinical pipeline for treatment formulations for diabetic macular edema. Licensing and patenting of products before distribution is an essential criterion, which is separating established players from their emerging competitors.
Key instances of the recent development in the market include:
- Novartis announced in March 2022 that the European Commission had approved Beovu, a treatment for diabetic macular edema.
- To treat age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema, Japanese pharmaceutical giant Chugai received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in March 2022 for Vabysmo (faricimab) for intravitreal injection (DME).
Scope Of The Diabetic Macular Edema Market Report
|
Attribute |
Details |
|
Estimated Market Size (2022) |
US$ 3.7 Billion |
|
Projected Market Valuation (2032) |
US$ 4.2 Billion |
|
Value-based CAGR (2022 to 2032) |
1.2% |
|
Forecast Period |
2017 to 2021 |
|
Historical Data Available for |
2022 to 2032 |
|
Market Analysis |
Value (US$ Billion) |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa (MEA) |
|
Key Countries Covered |
The USA, Canada, Brazil, Mexico, Argentina, The UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
|
Key Market Segments Covered |
Drug, Form, Distribution Channel, and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Key Segments Covered In Diabetic Macular Edema Market Report
By Drug:
- Anti-VEGF
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Corticosteroid Therapies
- Dexamethasone (Ozurdex)
- Fluocinolone Acetonide (Iluvien)
- Other Off-label Drugs
By Form:
- Intravitreal Injections
- Intravitreal Implants
By Distribution Channel:
- Hospitals
- Specialty Clinics
- Mail Order Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
How large is the global diabetic macular edema market?
The global diabetic macular edema market was valued at around US$ 3.2 Billion in 2021.
What is the sales forecast for the diabetic macular edema market through 2032?
Sales in the diabetic macular edema market are set to witness a CAGR of 1.2% and be valued at around US$ 4.2 Billion by 2032.
What was the historical CAGR of the diabetic macular edema market?
The global diabetic macular edema market increased at 18.1% CAGR from 2017 to 2021.
Which countries are set to drive demand in the diabetic macular edema market?
The USA, China, Germany, Japan, and Australia account for the majority of the diabetic macular edema market share and they are currently holding 71.5% of the share.
What is the USA diabetic macular edema market outlook?
The USA accounted for around 58.0% of the share in the global diabetic macular edema market in 2021.
Who are the top four manufacturers in the diabetic macular edema market?
Novartis AG, Bayer AG, Allergan Plc., and F. Hoffmann-La Roche Ltd., are the top four manufacturers in the diabetic macular edema market.
How is the diabetic macular edema market in China shaping up?
The China diabetic macular edema market held a share of about 4.3% in 2021.
How is the diabetic macular edema market in Japan progressing?
The Japan diabetic macular edema market held a share of about 3.0% in 2021.
What is the expected growth outlook of the diabetic macular edema market in Germany?
The Germany diabetic macular edema market holds a share of around 3.2%.
Who are the key players in the diabetic macular edema market?
Some of the key players in the diabetic macular edema market include Novartis AG, Bayer AG, Allergan Plc., F. Hoffmann-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.), KalVista Pharmaceuticals, Genentech, Oxurion (fka ThromboGenics), Ocugen, Inc, Regeneron Pharmaceuticals, Inc., Clearside Biomedical, Daiichi Sankyo, Chugai Pharmaceutical Co., Ltd., and Arctic Vision.
Table of Content
1. Executive Summary | Diabetic Macular Edema Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Drug Innovation / Development Trends 4. Key Success Factors 4.1. Promotional Strategies - By Key Manufacturers 4.2. Key Regulations 4.3. Value Chain Analysis 4.4. Regulatory Impositions 4.5. Reimbursement Scenario 4.6. Pipeline Analysis 4.7. PESTEL Analysis 4.8. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Diabetes Therapeutics Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Geriatric Age Group Population 5.2.2. Rising Research and Development Activities 5.2.3. Rising Prevalence of Diabetes 5.2.4. Emergence of New Therapeutic Drug Modalities 5.2.5. Drug Patent and Licensing Activities 5.2.6. Prevalence of Vision Loss 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Drug 6.1.2. By Form 6.1.3. By Distribution Channel 6.1.4. By Country 6.2. 2021 Market Scenario 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis By Drug 7.2. Pricing Break-up 7.2.1. Manufacturer-Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis Benchmark 7.4. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Billion) Analysis 2017 to 2021 and Forecast, 2022 to 2032 8.1. Historical Market Value (US$ Billion) Analysis, 2017 to 2021 8.2. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Billion) Analysis By Drug, 2017 to 2021 9.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Drug, 2022 to 2032 9.3.1. Anti-VEGF 9.3.1.1. Ranibizumab (Lucentis) 9.3.1.2. Aflibercept (Eylea) 9.3.2. Corticosteroid Therapies 9.3.2.1. Dexamethasone (Ozurdex) 9.3.2.2. Fluocinolone Acetonide (Iluvien) 9.3.3. Other Off-label Drugs 9.4. Market Attractiveness Analysis By Drug 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Form 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Billion) Analysis By Form, 2017 to 2021 10.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Form, 2022 to 2032 10.3.1. Intravitreal Injections 10.3.2. Intravitreal Implants 10.4. Market Attractiveness Analysis By Form 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Billion) Analysis By Distribution Channel, 2017 to 2021 11.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Distribution Channel, 2022 to 2032 11.3.1. Hospitals 11.3.2. Specialty Clinics 11.3.3. Mail Order Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Billion) Analysis By Region, 2017 to 2021 12.3. Current and Future Market Size (US$ Billion) Analysis and Forecast By Region, 2022 to 2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East & Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 13.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. The USA 13.3.1.2. Canada 13.3.2. By Drug 13.3.3. By Form 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug 13.4.3. By Form 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. The USA Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast By Market Taxonomy 13.8.1.2.1. By Country 13.8.1.2.2. By Drug 13.8.1.2.3. By Form 13.8.1.2.4. By Distribution Channel 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast By Market Taxonomy 13.8.2.2.1. By Country 13.8.2.2.2. By Drug 13.8.2.2.3. By Form 13.8.2.2.4. By Distribution Channel 14. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 14.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.1.4.1. By Country 14.3.1.4.2. By Drug 14.3.1.4.3. By Form 14.3.1.4.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1.1.1. By Country 14.4.1.1.2. By Drug 14.4.1.1.3. By Form 14.4.1.1.4. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast By Market Taxonomy 14.8.1.2.1. By Drug 14.8.1.2.2. By Form 14.8.1.2.3. By Distribution Channel 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast By Market Taxonomy 14.8.2.2.1. By Country 14.8.2.2.2. By Drug 14.8.2.2.3. By Form 14.8.2.2.4. By Distribution Channel 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast By Market Taxonomy 14.8.3.2.1. By Drug 14.8.3.2.2. By Form 14.8.3.2.3. By Distribution Channel 15. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 15.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. The UK 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Drug 15.3.3. By Form 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug 15.4.3. By Form 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast By Market Taxonomy 15.8.1.2.1. By Drug 15.8.1.2.2. By Form 15.8.1.2.3. By Distribution Channel 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast By Market Taxonomy 15.8.2.2.1. By Drug 15.8.2.2.2. By Form 15.8.2.2.3. By Distribution Channel 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast By Market Taxonomy 15.8.3.2.1. By Drug 15.8.3.2.2. By Form 15.8.3.2.3. By Distribution Channel 15.8.4. The UK Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast By Market Taxonomy 15.8.4.2.1. By Drug 15.8.4.2.2. By Form 15.8.4.2.3. By Distribution Channel 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast By Market Taxonomy 15.8.5.2.1. By Drug 15.8.5.2.2. By Form 15.8.5.2.3. By Distribution Channel 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast By Market Taxonomy 15.8.6.2.1. By Drug 15.8.6.2.2. By Form 15.8.6.2.3. By Distribution Channel 15.8.7. Russia Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast By Market Taxonomy 15.8.7.2.1. By Drug 15.8.7.2.2. By Form 15.8.7.2.3. By Distribution Channel 16. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 16.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug 16.3.3. By Form 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug 16.4.3. By Form 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast By Market Taxonomy 16.8.1.2.1. By Drug 16.8.1.2.2. By Form 16.8.1.2.3. By Distribution Channel 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast By Market Taxonomy 16.8.2.2.1. By Drug 16.8.2.2.2. By Form 16.8.2.2.3. By Distribution Channel 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast By Market Taxonomy 16.8.3.2.1. By Drug 16.8.3.2.2. By Form 16.8.3.2.3. By Distribution Channel 17. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 17.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Drug 17.3.3. By Form 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug 17.4.3. By Form 17.4.4. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast By Market Taxonomy 17.8.1.2.1. By Drug 17.8.1.2.2. By Form 17.8.1.2.3. By Distribution Channel 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast By Market Taxonomy 17.8.2.2.1. By Drug 17.8.2.2.2. By Form 17.8.2.2.3. By Distribution Channel 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast By Market Taxonomy 17.8.3.2.1. By Drug 17.8.3.2.2. By Form 17.8.3.2.3. By Distribution Channel 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast By Market Taxonomy 17.8.4.2.1. By Drug 17.8.4.2.2. By Form 17.8.4.2.3. By Distribution Channel 18. Oceania Market 2017 to 2021 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 18.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug 18.3.3. By Form 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug 18.4.3. By Form 18.4.4. By Distribution Channel 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. Australia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast By Market Taxonomy 18.7.1.2.1. By Drug 18.7.1.2.2. By Form 18.7.1.2.3. By Distribution Channel 18.7.2. New Zealand Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast By Market Taxonomy 18.7.2.2.1. By Drug 18.7.2.2.2. By Form 18.7.2.2.3. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2017 to 2021 and Forecast 2022 to 2032 19.1. Introduction 19.2. Historical Market Size (US$ Billion) Trend Analysis By Market Taxonomy, 2017 to 2021 19.3. Current and Future Market Size (US$ Billion) Analysis & Forecast By Market Taxonomy, 2022 to 2032 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Turkey 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Drug 19.3.3. By Form 19.3.4. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug 19.4.3. By Form 19.4.4. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country-Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast By Market Taxonomy 19.8.1.2.1. By Drug 19.8.1.2.2. By Form 19.8.1.2.3. By Distribution Channel 19.8.2. Turkey Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast By Market Taxonomy 19.8.2.2.1. By Drug 19.8.2.2.2. By Form 19.8.2.2.3. By Distribution Channel 19.8.3. South Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast By Market Taxonomy 19.8.3.2.1. By Drug 19.8.3.2.2. By Form 19.8.3.2.3. By Distribution Channel 19.8.4. North Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast By Market Taxonomy 19.8.4.2.1. By Drug 19.8.4.2.2. By Form 19.8.4.2.3. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis By Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis (%) of Top Players 20.4. Market Presence Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. Novartis AG 21.3.1.1. Overview 21.3.1.2. Drug Portfolio 21.3.1.3. Sales Footprint 21.3.1.4. Key Financials 21.3.1.5. SWOT Analysis 21.3.1.6. Strategic Overview 21.3.2. Bayer AG 21.3.2.1. Overview 21.3.2.2. Drug Portfolio 21.3.2.3. Sales Footprint 21.3.2.4. Key Financials 21.3.2.5. SWOT Analysis 21.3.2.6. Strategic Overview 21.3.3. Allergan Plc. 21.3.3.1. Overview 21.3.3.2. Drug Portfolio 21.3.3.3. Sales Footprint 21.3.3.4. Key Financials 21.3.3.5. SWOT Analysis 21.3.3.6. Strategic Overview 21.3.4. F. Hoffman-La Roche Ltd. 21.3.4.1. Overview 21.3.4.2. Drug Portfolio 21.3.4.3. Sales Footprint 21.3.4.4. Key Financials 21.3.4.5. SWOT Analysis 21.3.4.6. Strategic Overview 21.3.5. Alimera Sciences Inc. 21.3.5.1. Overview 21.3.5.2. Drug Portfolio 21.3.5.3. Sales Footprint 21.3.5.4. Key Financials 21.3.5.5. SWOT Analysis 21.3.5.6. Strategic Overview 21.3.6. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.) 21.3.6.1. Overview 21.3.6.2. Drug Portfolio 21.3.6.3. Sales Footprint 21.3.6.4. Key Financials 21.3.6.5. SWOT Analysis 21.3.6.6. Strategic Overview 21.3.7. KalVista Pharmaceuticals 21.3.7.1. Overview 21.3.7.2. Drug Portfolio 21.3.7.3. Sales Footprint 21.3.7.4. Key Financials 21.3.7.5. SWOT Analysis 21.3.7.6. Strategic Overview 21.3.8. Genentech 21.3.8.1. Overview 21.3.8.2. Drug Portfolio 21.3.8.3. Sales Footprint 21.3.8.4. Key Financials 21.3.8.5. SWOT Analysis 21.3.8.6. Strategic Overview 21.3.9. Oxurion (fka ThromboGenics) 21.3.9.1. Overview 21.3.9.2. Drug Portfolio 21.3.9.3. Sales Footprint 21.3.9.4. Key Financials 21.3.9.5. SWOT Analysis 21.3.9.6. Strategic Overview 21.3.10. Ocugen, Inc 21.3.10.1. Overview 21.3.10.2. Drug Portfolio 21.3.10.3. Sales Footprint 21.3.10.4. Key Financials 21.3.10.5. SWOT Analysis 21.3.10.6. Strategic Overview 21.3.11. Regeneron Pharmaceuticals, Inc. 21.3.11.1. Overview 21.3.11.2. Drug Portfolio 21.3.11.3. Sales Footprint 21.3.11.4. Key Financials 21.3.11.5. SWOT Analysis 21.3.11.6. Strategic Overview 21.3.12. Clearside Biomedical 21.3.12.1. Overview 21.3.12.2. Drug Portfolio 21.3.12.3. Sales Footprint 21.3.12.4. Key Financials 21.3.12.5. SWOT Analysis 21.3.12.6. Strategic Overview 21.3.13. Daiichi Sankyo 21.3.13.1. Overview 21.3.13.2. Drug Portfolio 21.3.13.3. Sales Footprint 21.3.13.4. Key Financials 21.3.13.5. SWOT Analysis 21.3.13.6. Strategic Overview 21.3.14. Arctic Vision 21.3.14.1. Overview 21.3.14.2. Drug Portfolio 21.3.14.3. Sales Footprint 21.3.14.4. Key Financials 21.3.14.5. SWOT Analysis 21.3.14.6. Strategic Overview 22. Assumptions and Acronyms Used 23. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 02: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032 by Form Table 03: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 04: Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Region Table 05: North America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 06: North America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 07: North America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Form Table 08: North America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 09: Latin America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 10: Latin America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 11: Latin America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Form Table 12: Latin America Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 13: Europe Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 14: Europe Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 15: Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032 by Form Table 16: Europe Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 17: East Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 18: East Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 19: East Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Form Table 20: East Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 21: South Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 22: South Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 23: South Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Form Table 24: South Asia Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 25: Oceania Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 26: Oceania Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 27: Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032 by Form Table 28: Oceania Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 29: Middle East & Africa Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Country Table 30: Middle East & Africa Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Drug Table 31: Middle East & Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032 by Form Table 32: Middle East & Africa Market Value (US$ Billion) Analysis 2017 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032 Figure 03: Global Market Absolute $ Opportunity (US$ Billion) Analysis, 2021 to 2032 Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Drug Figure 05: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Drug Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Drug Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Form Figure 08: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Form Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Form Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by Distribution Channel Figure 11: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Distribution Channel Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by Distribution Channel Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Region Figure 14: Global Market Y-o-Y Growth (%) Analysis 2021 to 2032, by Region Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Region Figure 16: North America Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 17: North America Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 18: North America Market Value Share, by Drug (2022 E) Figure 19: North America Market Value Share, by Form (2022 E) Figure 20: North America Market Value Share, by Distribution Channel (2022 E) Figure 21: North America Market Value Share, by Country (2022 E) Figure 22: North America Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 23: North America Market Attractiveness Analysis by Form, 2022 to 2032 Figure 24: North America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 26: U.S. Market Value Proportion Analysis, 2021 Figure 27: Global Vs. U.S. Growth Comparison Figure 28: U.S. Market Share Analysis (%) by Drug, 2021 to 2032 Figure 29: U.S. Market Share Analysis (%) by Form, 2021 to 2032 Figure 30: U.S. Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 31: Canada Market Value Proportion Analysis, 2021 Figure 32: Global Vs. Canada. Growth Comparison Figure 33: Canada Market Share Analysis (%) by Drug, 2021 to 2032 Figure 34: Canada Market Share Analysis (%) by Form, 2021 to 2032 Figure 35: Canada Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 36: Latin America Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 37: Latin America Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 38: Latin America Market Value Share, by Drug (2022 E) Figure 39: Latin America Market Value Share, by Form (2022 E) Figure 40: Latin America Market Value Share, by Distribution Channel (2022 E) Figure 41: Latin America Market Value Share, by Country (2022 E) Figure 42: Latin America Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 43: Latin America Market Attractiveness Analysis by Form, 2022 to 2032 Figure 44: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 45: Latin America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 46: Mexico Market Value Proportion Analysis, 2021 Figure 47: Global Vs Mexico Growth Comparison Figure 48: Mexico Market Share Analysis (%) by Drug, 2021 to 2032 Figure 49: Mexico Market Share Analysis (%) by Form, 2021 to 2032 Figure 50: Mexico Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 51: Brazil Market Value Proportion Analysis, 2021 Figure 52: Global Vs. Brazil. Growth Comparison Figure 53: Brazil Market Share Analysis (%) by Drug, 2021 to 2032 Figure 54: Brazil Market Share Analysis (%) by Form, 2021 to 2032 Figure 55: Brazil Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 56: Argentina Market Value Proportion Analysis, 2021 Figure 57: Global Vs Argentina Growth Comparison Figure 58: Argentina Market Share Analysis (%) by Drug, 2021 to 2032 Figure 59: Argentina Market Share Analysis (%) by Form, 2021 to 2032 Figure 60: Argentina Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 61: Europe Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 62: Europe Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 63: Europe Market Value Share, by Drug (2022 E) Figure 64: Europe Market Value Share, by Form (2022 E) Figure 65: Europe Market Value Share, by Distribution Channel (2022 E) Figure 66: Europe Market Value Share, by Country (2022 E) Figure 67: Europe Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 68: Europe Market Attractiveness Analysis by Form, 2022 to 2032 Figure 69: Europe Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 70: Europe Market Attractiveness Analysis by Country, 2022 to 2032 Figure 71: UK Market Value Proportion Analysis, 2021 Figure 72: Global Vs. UK Growth Comparison Figure 73: UK Market Share Analysis (%) by Drug, 2021 to 2032 Figure 74: UK Market Share Analysis (%) by Form, 2021 to 2032 Figure 75: UK Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 76: Germany Market Value Proportion Analysis, 2021 Figure 77: Global Vs. Germany Growth Comparison Figure 78: Germany Market Share Analysis (%) by Drug, 2021 to 2032 Figure 79: Germany Market Share Analysis (%) by Form, 2021 to 2032 Figure 80: Germany Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 81: Italy Market Value Proportion Analysis, 2021 Figure 82: Global Vs. Italy Growth Comparison Figure 83: Italy Market Share Analysis (%) by Drug, 2021 to 2032 Figure 84: Italy Market Share Analysis (%) by Form, 2021 to 2032 Figure 85: Italy Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 86: France Market Value Proportion Analysis, 2021 Figure 87: Global Vs France Growth Comparison Figure 88: France Market Share Analysis (%) by Drug, 2021 to 2032 Figure 89: France Market Share Analysis (%) by Form, 2021 to 2032 Figure 90: France Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 91: Spain Market Value Proportion Analysis, 2021 Figure 92: Global Vs Spain Growth Comparison Figure 93: Spain Market Share Analysis (%) by Drug, 2021 to 2032 Figure 94: Spain Market Share Analysis (%) by Form, 2021 to 2032 Figure 95: Spain Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 96: Russia Market Value Proportion Analysis, 2021 Figure 97: Global Vs Russia Growth Comparison Figure 98: Russia Market Share Analysis (%) by Drug, 2021 to 2032 Figure 99: Russia Market Share Analysis (%) by Form, 2021 to 2032 Figure 100: Russia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 101: BENELUX Market Value Proportion Analysis, 2021 Figure 102: Global Vs BENELUX Growth Comparison Figure 103: BENELUX Market Share Analysis (%) by Drug, 2021 to 2032 Figure 104: BENELUX Market Share Analysis (%) by Form, 2021 to 2032 Figure 105: BENELUX Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 106: East Asia Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 107: East Asia Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 108: East Asia Market Value Share, by Drug (2022 E) Figure 109: East Asia Market Value Share, by Form (2022 E) Figure 110: East Asia Market Value Share, by Distribution Channel (2022 E) Figure 111: East Asia Market Value Share, by Country (2022 E) Figure 112: East Asia Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 113: East Asia Market Attractiveness Analysis by Form, 2022 to 2032 Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 115: East Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 116: China Market Value Proportion Analysis, 2021 Figure 117: Global Vs. China Growth Comparison Figure 118: China Market Share Analysis (%) by Drug, 2021 to 2032 Figure 119: China Market Share Analysis (%) by Form, 2021 to 2032 Figure 120: China Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 121: Japan Market Value Proportion Analysis, 2021 Figure 122: Global Vs. Japan Growth Comparison Figure 123: Japan Market Share Analysis (%) by Drug, 2021 to 2032 Figure 124: Japan Market Share Analysis (%) by Form, 2021 to 2032 Figure 125: Japan Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 126: South Korea Market Value Proportion Analysis, 2021 Figure 127: Global Vs South Korea Growth Comparison Figure 128: South Korea Market Share Analysis (%) by Drug, 2021 to 2032 Figure 129: South Korea Market Share Analysis (%) by Form, 2021 to 2032 Figure 130: South Korea Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 131: South Asia Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 132: South Asia Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 133: South Asia Market Value Share, by Drug (2022 E) Figure 134: South Asia Market Value Share, by Form (2022 E) Figure 135: South Asia Market Value Share, by Distribution Channel (2022 E) Figure 136: South Asia Market Value Share, by Country (2022 E) Figure 137: South Asia Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 138: South Asia Market Attractiveness Analysis by Form, 2022 to 2032 Figure 139: South Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 140: South Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 141: India Market Value Proportion Analysis, 2021 Figure 142: Global Vs. India Growth Comparison Figure 143: India Market Share Analysis (%) by Drug, 2021 to 2032 Figure 144: India Market Share Analysis (%) by Form, 2021 to 2032 Figure 145: India Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 146: Indonesia Market Value Proportion Analysis, 2021 Figure 147: Global Vs. Indonesia Growth Comparison Figure 148: Indonesia Market Share Analysis (%) by Drug, 2021 to 2032 Figure 149: Indonesia Market Share Analysis (%) by Form, 2021 to 2032 Figure 150: Indonesia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 151: Malaysia Market Value Proportion Analysis, 2021 Figure 152: Global Vs. Malaysia Growth Comparison Figure 153: Malaysia Market Share Analysis (%) by Drug, 2021 to 2032 Figure 154: Malaysia Market Share Analysis (%) by Form, 2021 to 2032 Figure 155: Malaysia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 156: Thailand Market Value Proportion Analysis, 2021 Figure 157: Global Vs. Thailand Growth Comparison Figure 158: Thailand Market Share Analysis (%) by Drug, 2021 to 2032 Figure 159: Thailand Market Share Analysis (%) by Form, 2021 to 2032 Figure 160: Thailand Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 161: Oceania Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 162: Oceania Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 163: Oceania Market Value Share, by Drug (2022 E) Figure 164: Oceania Market Value Share, by Form (2022 E) Figure 165: Oceania Market Value Share, by Distribution Channel (2022 E) Figure 166: Oceania Market Value Share, by Country (2022 E) Figure 167: Oceania Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 168: Oceania Market Attractiveness Analysis by Form, 2022 to 2032 Figure 169: Oceania Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 170: Oceania Market Attractiveness Analysis by Country, 2022 to 2032 Figure 171: Australia Market Value Proportion Analysis, 2021 Figure 172: Global Vs. Australia Growth Comparison Figure 173: Australia Market Share Analysis (%) by Drug, 2021 to 2032 Figure 174: Australia Market Share Analysis (%) by Form, 2021 to 2032 Figure 175: Australia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 176: New Zealand Market Value Proportion Analysis, 2021 Figure 177: Global Vs New Zealand Growth Comparison Figure 178: New Zealand Market Share Analysis (%) by Drug, 2021 to 2032 Figure 179: New Zealand Market Share Analysis (%) by Form, 2021 to 2032 Figure 180: New Zealand Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 181: Middle East & Africa Market Value (US$ Billion) Analysis, 2017 to 2021 Figure 182: Middle East & Africa Market Value (US$ Billion) Forecast, 2022 to 2032 Figure 183: Middle East & Africa Market Value Share, by Drug (2022 E) Figure 184: Middle East & Africa Market Value Share, by Form (2022 E) Figure 185: Middle East & Africa Market Value Share, by Distribution Channel (2022 E) Figure 186: Middle East & Africa Market Value Share, by Country (2022 E) Figure 187: Middle East & Africa Market Attractiveness Analysis by Drug, 2022 to 2032 Figure 188: Middle East & Africa Market Attractiveness Analysis by Form, 2022 to 2032 Figure 189: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032 Figure 191: GCC Countries Market Value Proportion Analysis, 2021 Figure 192: Global Vs GCC Countries Growth Comparison Figure 193: GCC Countries Market Share Analysis (%) by Drug, 2021 to 2032 Figure 194: GCC Countries Market Share Analysis (%) by Form, 2021 to 2032 Figure 195: GCC Countries Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 196: Turkey Market Value Proportion Analysis, 2021 Figure 197: Global Vs. Turkey Growth Comparison Figure 198: Turkey Market Share Analysis (%) by Drug, 2021 to 2032 Figure 199: Turkey Market Share Analysis (%) by Form, 2021 to 2032 Figure 200: Turkey Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 201: South Africa Market Value Proportion Analysis, 2021 Figure 202: Global Vs. South Africa Growth Comparison Figure 203: South Africa Market Share Analysis (%) by Drug, 2021 to 2032 Figure 204: South Africa Market Share Analysis (%) by Form, 2021 to 2032 Figure 205: South Africa Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 206: North Africa Market Value Proportion Analysis, 2021 Figure 207: Global Vs North Africa Growth Comparison Figure 208: North Africa Market Share Analysis (%) by Drug, 2021 to 2032 Figure 209: North Africa Market Share Analysis (%) by Form, 2021 to 2032 Figure 210: North Africa Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Recommendations
Explore Healthcare Insights
View Reports
